Rigel Pharmaceuticals, Inc. · FWB:RI2

Rigel Pharmaceuticals, Inc. financial statements

Rigel Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue294.3M179.3M116.9M120.2M149.2M108.6M59.3M44.5M4.48M20.4M
Cost of revenue19.6M18.6M7.11M1.75M1.08M895.0K906.0K287.0K46.3M63.4M
Gross profit274.7M160.6M109.8M118.5M148.2M107.7M58.4M44.2M-41.8M-43.1M
Research and development33.3M23.4M24.5M60.3M65.2M60.1M52.9M46.9M46.3M63.4M
Selling, general and administrative115.9M113.1M105.7M112.5M91.9M76.6M74.6M70.0M37.8M20.9M
Operating income125.5M24.2M-20.5M-55.5M-12.5M-29.0M-69.1M-72.7M-79.6M-69.7M
Depreciation and amortization2.42M2.23M1.24M998.0K1.16M706.0K683.0K594.0K465.0K941.0K
EBITDA127.9M26.4M-19.3M-54.6M-11.3M-28.3M-68.4M-72.1M-79.2M-68.8M
Interest expense7.32M7.92M6.87M3.71M4.86M1.35M335.0K000
Income before tax121.8M18.4M-25.1M-58.6M-17.3M-29.7M-66.9M-70.5M-78.0M-69.2M
Income tax-245.2M881.0K03.02M605.0K647.0K-348.0K000
Net income367.0M17.5M-25.1M-58.6M-17.9M-29.7M-66.9M-70.5M-78.0M-69.2M
Earnings per share, basic20.400.99-1.44-3.44-0.11-0.18-0.40-0.44-0.62-0.73
Earnings per share, diluted19.480.99-1.44-3.44-0.11-0.18-0.40-0.44-0.62-0.73

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents40.6M56.7M32.8M24.5M18.9M30.4M22.5M76.3M38.3M17.6M
Short-term investments114.4M20.6M24.1M33.7M106.1M27.0M75.6M52.2M77.5M57.1M
Receivables51.8M41.6M30.6M40.3M15.5M16.0M10.1M4.08M00
Inventory11.5M6.00M5.52M9.12M6.62M1.64M1.35M894.0K00
Current assets240.2M135.1M99.3M115.9M154.5M89.0M119.0M137.0M117.4M76.2M
Property, plant and equipment30.0K92.0K165.0K857.0K2.18M2.68M2.16M1.39M875.0K1.16M
Goodwill00
Total assets513.6M164.0M117.2M134.3M167.3M110.4M147.6M139.1M119.1M78.1M
Accounts payable7.19M3.34M7.14M22.5M3.79M3.71M4.15M6.39M2.64M5.56M
Current liabilities99.2M63.3M53.3M65.2M63.6M40.8M58.2M27.7M18.3M22.6M
Long-term debt22.5M52.4M52.4M39.4M19.9M19.8M9.81M00
Total debt52.5M60.0M60.0M40.0M20.0M20.0M10.0M284.0K3.46M
Total liabilities122.1M160.7M145.9M147.9M137.0M76.4M93.8M29.2M18.5M23.1M
Shareholders' equity391.5M3.29M-28.6M-13.6M30.4M34.0M53.8M109.9M100.6M55.0M
Shares outstanding18.3M17.7M17.5M173.4M171.6M169.3M168.0M167.2M146.8M99.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations75.7M31.5M-5.74M-73.8M5.88M-52.2M-41.5M-58.8M-77.6M-75.9M
Capital spending0-396.0K-15.0M-450.0K-627.0K-1.26M-1.46M-1.11M-164.0K-804.0K
Free cash flow75.7M31.1M-20.7M-74.2M5.25M-53.4M-43.0M-59.9M-77.7M-76.7M
Cash from investing-92.4M4.13M-4.30M72.8M-80.0M47.5M-23.7M25.0M-19.5M24.9M
Cash from financing601.0K-11.6M18.4M6.55M62.7M12.6M11.4M71.9M117.7M25.2M
Dividends paid00
Share buybacks0-10.0M02.12M4.78M2.60M1.58M71.9M117.7M25.2M
Change in cash-16.1M24.0M8.33M5.57M-11.5M7.85M-53.8M38.0M20.7M-25.8M